Atlas Trials

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Clinical trial NCT05983276 · RECRUITING

Trial details

NCT number
NCT05983276
Sponsor
Loyola University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2023-11-16
Primary completion
2030-08-28
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.